RxDoctor Payments Data

Uzochukwu Unegbu, MD

Family Medicine · Laurel, MDNPI 1104006360

Payments from drug & device makers

$5,323in general payments, 2019–2025

Across 247 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$584
  • Acadia Pharmaceuticals Inc$471
  • Sunovion Pharmaceuticals Inc.$445
  • Gilead$413
  • Sumitomo Pharma America, Inc.$318
  • AstraZeneca$299
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$5,25899%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,323 in reported general payments places this provider in the 90th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$285,468
Medicare patients
414
Services billed
2,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$180,898
EliquisApixaban581$179,211
JardianceEmpagliflozin165$55,321
OzempicSemaglutide46$54,567
TrulicityDulaglutide78$53,296
Sevelamer Carbonate51$43,850
XareltoRivaroxaban111$42,396
NuplazidPimavanserin Tartrate11$29,173
XifaxanRifaximin24$24,085
JanuviaSitagliptin Phosphate70$22,087
RexultiBrexpiprazole43$21,772
Atorvastatin Calcium1,135$19,674
KerendiaFinerenone23$19,362
AptiomEslicarbazepine Acetate19$14,250
Levetiracetam290$13,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$256$179,211581 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$102$72,736206 claims
Novo NordiskOzempic$295$54,56746 claims
Lilly USA, LLCTrulicity$75$53,29678 claims
Johnson & JohnsonXarelto$19$42,396111 claims
Acadia Pharmaceuticals IncNuplazid$471$29,17311 claims
Otsuka America Pharmaceutical, Inc.Rexulti$180$21,77243 claims
BayerKerendia$584$19,36223 claims
Sunovion Pharmaceuticals Inc.Aptiom$445$14,25019 claims
GSKBreo Ellipta$19$10,22724 claims
Sanofi-aventis U.S. LLCMultaq$199$8,70512 claims
AstraZenecaBrilinta$299$7,83435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Laurel

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →